Agonists of prostaglandin E 2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies - Université Paris Cité
Journal Articles Proceedings of the National Academy of Sciences of the United States of America Year : 2022

Agonists of prostaglandin E 2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies

Abstract

Juvenile nephronophthisis (NPH) is a renal ciliopathy due to a dysfunction of primary cilia for which no curative treatment is available. This paper describes the identification of agonists of prostaglandin E 2 receptors as a potential therapeutic approach for the most common NPHP1 -associated ciliopathies. We demonstrated that prostaglandin E 1 rescues defective ciliogenesis and ciliary composition in NPHP1 patient urine-derived renal tubular cells and improves ciliary and kidney phenotypes in our NPH zebrafish and Nphp1 −/− mouse models. In addition, Taprenepag alleviates the severe retinopathy observed in Nphp1 −/− mice. Finally, transcriptomic analyses pointed out several pathways downstream the prostaglandin receptors as cell cycle progression, extracellular matrix, or actin cytoskeleton organization. Altogether, our findings provide an alternative for treatment of NPH.
Fichier principal
Vignette du fichier
pnas.202115960.pdf (2.41 Mo) Télécharger le fichier
Origin Publication funded by an institution
Licence

Dates and versions

hal-03930843 , version 1 (01-10-2024)

Licence

Identifiers

Cite

Hugo Garcia, Alice Serafin, Flora Silbermann, Esther Porée, Amandine Viau, et al.. Agonists of prostaglandin E 2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 (18), pp.e2115960119. ⟨10.1073/pnas.2115960119⟩. ⟨hal-03930843⟩
23 View
0 Download

Altmetric

Share

More